HAVN — HAVN Life Sciences Share Price
Last trade - 00:00- CA$0.59m
- CA$0.60m
- CA$0.28m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.7 | ||
| Price to Tang. Book | 0.7 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -1779.71% | ||
| Return on Equity | -234.52% | ||
| Operating Margin | -2619.63% | ||
Financial Summary
| Year End 30th Apr | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | n/a | n/a | n/a | n/a | 0.28 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
HAVN Life Sciences Inc. is a Canada-based biotechnology company. The Company is focused on the standardized extraction of psychedelic compounds for the creation of active pharmaceutical ingredients (APIs), the development of natural health products, and therapies to support brain health and enhance the capabilities of the mind. It operates through two divisions: HAVN Labs and HAVN Retail. The HAVN Labs division is engaged in the development of research protocols to cover the production of Psilocybe spp. The Company's HAVN Retail division is focused on formulating and selling natural health products (NHPs) using compounds. It has product licenses, which are focused on four categories of human health and performance: immunity support, cognitive support, stress prevention, and energy support. It offers a range of quality mushroom and plant extracts that help boost immune function, reduce inflammation and support a healthy lifestyle.
Directors
- Last Annual
- April 30th, 2022
- Last Interim
- January 31st, 2023
- Incorporated
- April 8th, 2020
- Public Since
- August 11th, 2020
- No. of Employees
- 6
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Canadian Securities Exchange
- Shares in Issue
- 14,738,611
- Address
- 605 - 130 Brew Street, PORT MOODY, V3H 0E3
- Web
- https://havnlife.com/
- Phone
- +1 6043709520
- Auditors
- DeVisser Gray LLP
Upcoming Events for HAVN
Similar to HAVN
Albert Labs International
Canadian Securities Exchange
Algernon Pharmaceuticals
Canadian Securities Exchange
Alpha Cognition
Canadian Securities Exchange
Asep Medical Holdings
Canadian Securities Exchange
Avisa Diagnostics
Canadian Securities Exchange
FAQ
As of Today at 07:10 UTC, shares in HAVN Life Sciences are trading at CA$0.04. This share price information is delayed by 15 minutes.
Shares in HAVN Life Sciences last closed at CA$0.04 and the price had moved by -27.27% over the past 365 days. In terms of relative price strength the HAVN Life Sciences share price has underperformed the Toronto Stock Exchange 300 Composite Index by -25.01% over the past year.
There is no consensus recommendation for this security.
HAVN Life Sciences does not currently pay a dividend.
HAVN Life Sciences does not currently pay a dividend.
HAVN Life Sciences does not currently pay a dividend.
To buy shares in HAVN Life Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$0.04, shares in HAVN Life Sciences had a market capitalisation of CA$0.59m.
Here are the trading details for HAVN Life Sciences:
- Country of listing: Canada
- Exchange: CNX
- Ticker Symbol: HAVN
Based on an overall assessment of its quality, value and momentum HAVN Life Sciences is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like HAVN Life Sciences. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -38.22%.
As of the last closing price of CA$0.04, shares in HAVN Life Sciences were trading -76.79% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The HAVN Life Sciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.04.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on HAVN Life Sciences' directors